Found: 10
Select item for more details and to access through your institution.
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 7, p. 761, doi. 10.1007/s00262-005-0069-7
- By:
- Publication type:
- Article
Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
- Published in:
- Cancer Gene Therapy, 1999, v. 6, n. 1, p. 81, doi. 10.1038/sj.cgt.7700012
- By:
- Publication type:
- Article
Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 Therapy for Pediatric Acute Myeloid Leukemia.
- Published in:
- Pediatric Blood & Cancer, 2011, v. 57, n. 3, p. 398, doi. 10.1002/pbc.22966
- By:
- Publication type:
- Article
Affinity electrophoresis with monoclonal antibodies.
- Published in:
- Electrophoresis, 1987, v. 8, n. 7, p. 313, doi. 10.1002/elps.1150080704
- By:
- Publication type:
- Article
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 10, p. 1647, doi. 10.1007/s00262-018-2223-z
- By:
- Publication type:
- Article
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 9, p. 1047, doi. 10.1007/s00262-016-1864-z
- By:
- Publication type:
- Article
Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
- Published in:
- Cancer Immunology, Immunotherapy, 2013, v. 62, n. 8, p. 1303, doi. 10.1007/s00262-013-1430-x
- By:
- Publication type:
- Article
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 12, p. 2261, doi. 10.1007/s00262-012-1286-5
- By:
- Publication type:
- Article
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
- Published in:
- 1997
- By:
- Publication type:
- journal article